Inductive Bio placed first in the OpenADMET-ExpansionRx blind challenge with its Beacon models, a large-scale industry competition for ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) …
Read More
The modern obesity drug race has been defined by one word: incretins. Blockbuster GLP-1 receptor agonists from companies like Novo Nordisk and Eli Lilly have …
Read More
Despite rising trial costs and increasingly complex development timelines, one trend is clear: digital health technologies are rapidly moving from pilot programs to core components …
Read More
Eli Lilly has entered a collaboration with Seamless Therapeutics worth up to $1.12 billion to co-develop gene editing therapies targeting genetic forms of hearing loss. …
Read More
Washington- and California-based Nautilus Biotechnology is teaming up with Weill Cornell Medicine–Qatar and the Michael J. Fox Foundation (MJFF) for Parkinson’s Research on a new research …
Read More
The U.S. Food and Drug Administration has cleared Life Biosciences’ Investigational New Drug application for ER-100, allowing the Boston-based biotechnology company to begin a Phase …
Read More
